The Philadelphia Department of Public Health (PDPH) released an update on June 26, 2023. Below is a summary.
Prescribers currently registered with the DEA do not need a waiver to prescribe buprenorphine.
Starting June 27th, all prescribers renewing or applying for a new DEA registration will be required to complete training on treatment and management of opioid and substance use disorder.
Prescribers may treat new patients with buprenorphine following a telehealth evaluation, without an in-person physical exam or encounter, through November 11, 2023.
For patients who established care on or before November 11, 2023, prescribers may provider treatment with buprenorphine following a telehealth evaluation, without an in-person physical exam or encounter, through November 11, 2024.
